Jeremy D. Gale - Concepedia

Author

Jeremy D. Gale

Pfizer (United States)

Also Known As

Gale, J, J D Gale, J GALE, J GONZALEZ GALE, J Gale, J. D. GALE, J. D. Gale, J. GALE, J. Gale, J.D. Gale

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Pfizer (United Kingdom)University of Manchester University Clinical Hospital In Bialystok The Royal Free Hospital

About

Jeremy D. Gale is an author at Pfizer (United States) specializing in medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.3K
2	Health Sciences	6	6	186
3	Public Health	2	2	69
4	Allergy	1	1	43
5	Anesthesia	1	1	21

Jeremy D. Gale

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals Lasse Folkersen, Stefan Gustafsson, Qin Wang, Nature Metabolism CardiomyopathyHeart FailureCardiovascular DiseaseAtherosclerosisGenetics	2020	740
Effect of a second-generation α <sub>2</sub> δ ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome Lesley A. Houghton, Catherine Fell, Peter J. Whorwell, Gut	2007	199
GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity C. Gardner, Duncan Armour, David T. Beattie, Regulatory Peptides G Protein-coupled ReceptorMedicineDrug DiscoveryFunctional SelectivityImmunology	1996	145
GR113808: a novel, selective antagonist with high affinity at the 5‐HT<sub>4</sub> receptor Jeremy D. Gale, Carol J. Grossman, John W. F. Whitehead, British Journal of Pharmacology	1994	142
The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK<sub>1</sub> receptor antagonist GR203040 C. Gardner, D.J. Twissell, Timothy Dale, British Journal of Pharmacology	1995	122
Online High-Flow Peptide Immunoaffinity Enrichment and Nanoflow LC-MS/MS: Assay Development for Total Salivary Pepsin/Pepsinogen Hendrik Neubert, Jeremy D. Gale, David Muirhead Clinical Chemistry	2010	96
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study William J. Sandborn, Silvio Danese, Jarosław Leszczyszyn, Clinical Gastroenterology and Hepatology Gastrointestinal PharmacologyPhase 2BModerate-to-severe Ulcerative ColitisPharmacologyGastroenterology	2023	82
Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy Wim H. Scheele, Susan M. Diamond, Jeremy D. Gale, Journal of the American Society of Nephrology	2016	64
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation Pinelopi Manousou, Andrew K. Burroughs, Emmanuel Tsochatzis, Journal of Hepatology Digital PathologyPathologyCirrhosisDigital Image AnalysisDiagnostic Imaging	2012	59
Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study Rosalind Walley, Claire Smith, Jeremy D. Gale, Pharmaceutical Statistics Bayesian StatisticBayesian AssuranceEvidence-based MedicineBayesian FrameworkBayesian Inference	2015	56

Page 1